Bausch + Lomb (NYSE:BLCO) Announces Earnings Results, Misses Estimates By $0.02 EPS

Bausch + Lomb (NYSE:BLCO) released its quarterly earnings data on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.02), Briefing.com reports. The business had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.06 billion. Bausch + Lomb had a positive return on equity of 3.60% and a negative net margin of 7.81%. The company’s revenue was up 18.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.10 EPS. Bausch + Lomb updated its FY 2024 guidance to EPS.

Bausch + Lomb Stock Down 1.9 %

NYSE:BLCO traded down $0.26 on Friday, reaching $13.60. The stock had a trading volume of 533,395 shares, compared to its average volume of 641,173. Bausch + Lomb has a 12-month low of $13.16 and a 12-month high of $21.95. The firm’s fifty day moving average is $15.76 and its two-hundred day moving average is $15.60. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.09.

Analyst Ratings Changes

Several analysts recently commented on the stock. Barclays raised their price objective on shares of Bausch + Lomb from $17.00 to $18.00 and gave the company an “equal weight” rating in a research note on Monday, February 26th. Evercore decreased their price target on Bausch + Lomb from $17.00 to $15.00 and set an “in-line” rating on the stock in a research note on Thursday. Wells Fargo & Company lifted their price objective on Bausch + Lomb from $21.00 to $23.00 and gave the stock an “overweight” rating in a report on Thursday, February 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a research report on Wednesday. Finally, Evercore ISI raised their price target on Bausch + Lomb from $16.50 to $17.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Bausch + Lomb presently has an average rating of “Hold” and a consensus price target of $19.27.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.